Skip to main content

Table 1 Clinical characteristics of patients with localized SN-DLBCL and SN-ENKTL

From: Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma

Characteristic All patients
(n = 258), n (%)
SN-DLBCL
(n = 47), n (%)
SN-ENKTL
(n = 211), n (%)
p(SN-DLBCL vs. SN-ENKTL)
Sex
 Male 174 (67.4) 25 (53.2) 149 (70.6) 0.021
 Female 84 (32.6) 22 (46.8) 62 (29.4)
Age (year)
 Median (range) 43 (10–85) 63 (11–82) 40 (10–85) <0.001
 ≤60 225 (87.2) 25 (53.2) 200 (94.8)
 >60 33 (12.8) 22 (46.8) 11 (5.2)
Modified Ann Arbor stage
 Limited I 73 (28.3) 3 (6.4) 70 (33.2) 0.001
 Extensive I 126 (48.8) 32 (68.1) 94 (44.5)
 II 59 (22.9) 12 (25.5) 47 (22.3)
Nodal involvement
 Present 49 (19.0) 10 (21.3) 39 (18.5) 0.659
 Absent 209 (81.0) 37 (78.7) 172 (81.5)
B symptoms
 Present 104 (40.3) 5 (10.6) 99 (46.9) <0.001
 Absent 154 (59.7) 42 (89.4) 112 (53.1)
LDH level
 Normal 192 (74.4) 37 (78.7) 155 (73.5) 0.514
 Elevated 64 (24.8) 10 (21.3) 54 (25.6)
 Unknown 2 (0.8) 0 (0.0) 2 (0.9)
ECOG performance status
 0 141 (54.7) 25 (53.2) 116 (55.0) 0.018
 1 94 (36.4) 13 (27.7) 81 (38.4)
 ≥2 23 (8.9) 9 (19.1) 14 (6.6)
mIPI
 0 126 (48.8) 13 (27.7) 113 (53.6) 0.001
 1 92 (35.7) 20 (42.5) 72 (34.1)
 2–4 38 (14.7) 14 (29.8) 24 (11.4)
 Unknown 2 (0.8) 0 (0.0) 2 (0.9)
Treatment strategy
 CMT 147 (57.0) 37 (78.7) 110 (52.1) <0.001
 Chemotherapy alone 17 (6.6) 10 (21.3) 7 (3.3)
 Radiotherapy alone 94 (36.4) 0 (0.0) 94 (44.6)
Response to treatment
 CR/CRu 205 (79.5) 36 (76.6) 169 (80.1) 0.686
 PR 23 (8.9) 6 (12.7) 17 (8.1)
 SD 1 (0.4) 0 (0.0) 1 (0.5)
 PD 15 (5.8) 2 (4.3) 13 (6.2)
 Not evaluable 14 (5.4) 3 (6.4) 11 (5.1)
  1. SN-DLBCL sinonasal diffuse large B cell lymphoma, SN-ENKTL sinonasal extranodal NK/T cell lymphoma, LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, mIPI modified International Prognostic Index, CMT combined modality therapy, CR complete response, CRu unconfirmed complete response, PR partial response, SD stable disease, PD progressive disease